Friday, October 30, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 20, 2026

Mortgage rates climb higher as House passes home affordability bill

View original at finance.yahoo.com
Mortgage rates climb higher as House passes home affordability bill Mortgage rates continue to rise from spring levels, driven by the economic shocks from inflation, oil prices (CL=F, BZ=F), and the latest surge in Treasury yields (^TYX, ^TNX, ^FVX)…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The mortgage lock-in effect is keeping homeowners with low-rate (e.g., 3%) mortgages from moving, suppressing housing supply.

    60% confidence
  • Mortgage rates briefly fell below 6% earlier, and when rates get below 6% buyers come out and purchase homes.

    60% confidence
  • Mortgage rates are rising because of an absolute bond market rout, with the 10-year Treasury yield rising rapidly on investor inflation fears. The 10-year Treasury yield and mortgage rates are closely linked.

    60% confidence
  • The House version of the housing bill removed the Senate's 7-year mandatory disposal requirement for build-to-rent developers, creating a significant mismatch between the two bills.

    60% confidence
  • Lowe's has delivered four consecutive quarters of positive comparable sales with the DIY customer segment.

    60% confidence
  • Current mortgage rates are the highest levels of the year, occurring during the peak spring home buying season.

    60% confidence
  • Today, mortgage rates are 6.67%, which is actually better than yesterday when they were 6.75%.

    60% confidence
  • Home equity loan rates have also risen alongside mortgage rates, and construction costs are higher, making any home improvement activity difficult.

    60% confidence
  • The Senate version of the housing bill requires build-to-rent developers to sell their properties within seven years, which developers say would wreck their margins and business model.

    60% confidence
  • The House and Senate versions of the housing affordability bill differ significantly on the build-to-rent issue, making it unclear whether they can reconcile and send a final bill to President Trump.

    60% confidence
  • DIY customers make up approximately 60 to 65% of Lowe's revenue.

    60% confidence
  • Build-to-rent is a growing part of the real estate market because people cannot afford to buy homes but may want to rent a single-family home.

    60% confidence
  • Housing affordability advocates support build-to-rent because it contributes to housing supply and helps bring rents down.

    60% confidence
  • Home equity investments are a new, lightly regulated financial product where Wall Street gives homeowners upfront cash in exchange for a future cut of their home equity appreciation, without requiring regular payments. Homeowners whose property appreciates significantly can end up owing large sums.

    60% confidence
  • This is arguably the most difficult do-it-yourself housing environment since the financial crisis.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com